Bromocriptine treatment of systemic lupus erythematosus
Identifieur interne : 002407 ( Main/Exploration ); précédent : 002406; suivant : 002408Bromocriptine treatment of systemic lupus erythematosus
Auteurs : S E Walker [États-Unis]Source :
- Lupus [ 0961-2033 ] ; 2001-10.
English descriptors
- Teeft :
- Animal models, Arthritis rheum, Autoimmune, Autoimmune disease, Bromocriptine, Bromocriptine treatment, Bromocriptine treatment group, Clin, Disease activity, Dos, Erythematosus, Hyperprolactinemia, Immune, Immune responses, Immune system, Immunol, Internal medicine, Lupus, Lymphocyte, Mcmurray, Mood scales, Mood states, Pituitary glands, Pituitary secretion, Prolactin, Prolactin secretion, Receptor, Rheum, Serum prolactin, Serum prolactin concentrations, Symptom questionnaire, Symptom rating test, Systemic, Systemic lupus erythematosus, Therapeutic effect.
Abstract
Prolactin, a peptide hormone, acts as a cytokine. It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. This rationale has been applied to the treatment of systemic lupus erythematosus (SLE), a prototype autoimmune illness that occurs spontaneously in animal models such as the F1 hybrid NZB NZW mouse, and in humans. Treatment with bromocriptine was effective in treating some induced and spontaneous autoimmune disease in experimental models. Bromocriptine did slow the course of SLE in NZB NZW mice when treatment was started before the appearance of clinical disease. In addition, bromocriptine was effective in treating established disease in this model. In three separate clinical trials, bromocriptine showed evidence that it had a therapeutic effect in treating human lupus. Bromocriptine is currently considered an unproven therapy for SLE. Its use is entirely experimental. The fact that bromocriptine was effective in treating NZB-NZW mice, the beneficial therapeutic effects in human trials, and the low toxicity of the drug form a solid rationale for undertaking further therapeutic trials.
Url:
DOI: 10.1191/096120301717165010
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000848
- to stream Istex, to step Curation: 000848
- to stream Istex, to step Checkpoint: 001233
- to stream Main, to step Merge: 002432
- to stream Main, to step Curation: 002407
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bromocriptine treatment of systemic lupus erythematosus</title><author wicri:is="90%"><name sortKey="Walker, S E" sort="Walker, S E" uniqKey="Walker S" first="S E" last="Walker">S E Walker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D56C3E5BE8CD29506B4730FCB8A7208C9FA3906D</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1191/096120301717165010</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-9CCLV11S-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000848</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000848</idno><idno type="wicri:Area/Istex/Curation">000848</idno><idno type="wicri:Area/Istex/Checkpoint">001233</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001233</idno><idno type="wicri:doubleKey">0961-2033:2001:Walker S:bromocriptine:treatment:of</idno><idno type="wicri:Area/Main/Merge">002432</idno><idno type="wicri:Area/Main/Curation">002407</idno><idno type="wicri:Area/Main/Exploration">002407</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Bromocriptine treatment of systemic lupus erythematosus</title><author wicri:is="90%"><name sortKey="Walker, S E" sort="Walker, S E" uniqKey="Walker S" first="S E" last="Walker">S E Walker</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, The University of Missouri-Columbia, Columbia, Missouri, USA; Department of Internal Medicine, MA406G Health Sciences Center, One Hospital Drive, Columbia, MO 65212</wicri:regionArea><placeName><region type="state">Missouri (État)</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="2001-10">2001-10</date><biblScope unit="volume">10</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="762">762</biblScope><biblScope unit="page" to="768">768</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Animal models</term><term>Arthritis rheum</term><term>Autoimmune</term><term>Autoimmune disease</term><term>Bromocriptine</term><term>Bromocriptine treatment</term><term>Bromocriptine treatment group</term><term>Clin</term><term>Disease activity</term><term>Dos</term><term>Erythematosus</term><term>Hyperprolactinemia</term><term>Immune</term><term>Immune responses</term><term>Immune system</term><term>Immunol</term><term>Internal medicine</term><term>Lupus</term><term>Lymphocyte</term><term>Mcmurray</term><term>Mood scales</term><term>Mood states</term><term>Pituitary glands</term><term>Pituitary secretion</term><term>Prolactin</term><term>Prolactin secretion</term><term>Receptor</term><term>Rheum</term><term>Serum prolactin</term><term>Serum prolactin concentrations</term><term>Symptom questionnaire</term><term>Symptom rating test</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Therapeutic effect</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Prolactin, a peptide hormone, acts as a cytokine. It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. This rationale has been applied to the treatment of systemic lupus erythematosus (SLE), a prototype autoimmune illness that occurs spontaneously in animal models such as the F1 hybrid NZB NZW mouse, and in humans. Treatment with bromocriptine was effective in treating some induced and spontaneous autoimmune disease in experimental models. Bromocriptine did slow the course of SLE in NZB NZW mice when treatment was started before the appearance of clinical disease. In addition, bromocriptine was effective in treating established disease in this model. In three separate clinical trials, bromocriptine showed evidence that it had a therapeutic effect in treating human lupus. Bromocriptine is currently considered an unproven therapy for SLE. Its use is entirely experimental. The fact that bromocriptine was effective in treating NZB-NZW mice, the beneficial therapeutic effects in human trials, and the low toxicity of the drug form a solid rationale for undertaking further therapeutic trials.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Missouri (État)</li></region></list><tree><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Walker, S E" sort="Walker, S E" uniqKey="Walker S" first="S E" last="Walker">S E Walker</name></region><name sortKey="Walker, S E" sort="Walker, S E" uniqKey="Walker S" first="S E" last="Walker">S E Walker</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002407 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002407 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D56C3E5BE8CD29506B4730FCB8A7208C9FA3906D
|texte= Bromocriptine treatment of systemic lupus erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |